Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
59.58
-0.12 (-0.20%)
At close: Oct 8, 2026, 4:00 PM EDT
59.70
+0.12 (0.20%)
After-hours: Oct 8, 2026, 7:53 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.97B in the quarter ending June 30, 2026, with 5.74% growth. This brings the company's revenue in the last twelve months to $49.19B, up 3.11% year-over-year. In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%. That makes Bristol-Myers Squibb Company the 259th largest company in the world by revenue and 97th in the United States.
Revenue (ttm)
$49.19B
Revenue Growth
+3.11%
P/S Ratio
2.49
Revenue / Employee
$1,513,415
Employees
32,500
Market Cap
121.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
| Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
| Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
| Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
| Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
| Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
| Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
| Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
| Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
| Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
| Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
| Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
| Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
| Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
| Dec 31, 2005 | 18.61B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| GSK plc | 44.05B |
BMY News
- 13 hours ago - Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. - Business Wire
- 7 days ago - Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement - Business Wire
- 8 days ago - U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* - Business Wire
- 13 days ago - Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma - Business Wire
- 20 days ago - Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 - Business Wire
- 21 days ago - Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years - Business Wire
- 22 days ago - Bristol Myers Squibb Announces Dividend - Business Wire
- 4 weeks ago - Here are the stocks to favor in the fourth quarter — and those you should avoid - Market Watch